Literature DB >> 4056360

Suramin inhibits duck hepatitis B virus DNA polymerase activity.

K Tsiquaye, A Zuckerman.   

Abstract

Suramin, a polybasic anion, blocks the activity of the DNA polymerase encoded by the duck hepatitis B virus. The interaction with the virus was studied under conditions in which the property of the drug to bind with proteins was used with plasma obtained from infected ducks with viraemia. Inhibition of DNA polymerase activity associated with core particles from infected liver and circulating virions is irreversible, occurs in a dose-response fashion and suggests that inhibition results from suramin-virus interaction. The inhibition of the specific viral polymerase activity clearly indicates that this drug should be evaluated for the treatment of hepatitis B and infection caused by the related Hepadna viruses.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4056360     DOI: 10.1016/s0168-8278(85)80009-x

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  5 in total

Review 1.  100 Years of Suramin.

Authors:  Natalie Wiedemar; Dennis A Hauser; Pascal Mäser
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

2.  Suramin prevents duck hepatitis B virus infection in vivo.

Authors:  W B Offensperger; S Offensperger; E Walter; H E Blum; W Gerok
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

3.  ATP5B Is an Essential Factor for Hepatitis B Virus Entry.

Authors:  Keiji Ueda; Yadarat Suwanmanee
Journal:  Int J Mol Sci       Date:  2022-08-24       Impact factor: 6.208

4.  Proteoglycans act as cellular hepatitis delta virus attachment receptors.

Authors:  Oscar Lamas Longarela; Tobias T Schmidt; Katrin Schöneweis; Raffaella Romeo; Heiner Wedemeyer; Stephan Urban; Andreas Schulze
Journal:  PLoS One       Date:  2013-03-07       Impact factor: 3.240

5.  Screening and Evaluation of Novel Compounds against Hepatitis B Virus Polymerase Using Highly Purified Reverse Transcriptase Domain.

Authors:  Eriko Ohsaki; Keiji Ueda
Journal:  Viruses       Date:  2020-07-31       Impact factor: 5.048

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.